Another similar study found higher biomarker testing rates for EGFR, ALK, ROS1, and BRAF in patients with non‐squamous NSCLC compared with their overall population of patients with metastatic NSCLC.13 The gene discussed is ALK; the disease is non-small cell lung carcinoma.